Glenmark Pharmaceuticals receives ANDA approval for Azelaic Acid Gel, 15%

Deepthi | Myequity news | Date : 20-11-2018 10:30:00 IST

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Azelaic Acid Gel, 15%, a generic version of Finacea®1 Gel, 15%, of Leo Pharma A/S.

According to IQVIATM sales data for the 12 month period ending September 2018, the Finacea® Gel, 15% market2 achieved annual sales of approximately $64.1 million*.

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical organization. Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has several molecules in various stages of clinical development and is focused in the areas of oncology, dermatology and respiratory.

More from Myequity